SteadyMed to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
September 06 2016 - 11:37AM
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company
focused on the development of drug product candidates to treat
orphan and high-value diseases with unmet parenteral delivery
needs, today announced that Jonathan Rigby, President and Chief
Executive Officer, will present at the 18th Annual Rodman &
Renshaw Global Investment Conference, being held on September
11-13, 2016 at The Lotte New York Palace Hotel in New York City.
During the presentation, Mr. Rigby will provide an overview and
update on the company's business.
Date: Monday, September 12, 2016Time: 2:35 PM ETRoom: Louis
A live audio webcast and archive of the presentation will be
available through the Events and Presentations page of the
company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on
the development of drug products to treat orphan and high value
diseases with unmet parenteral delivery needs. The company's lead
drug product candidate is Trevyent®, a development stage drug
product that combines SteadyMed's PatchPump® technology with
treprostinil, a vasodilatory prostacyclin analogue to treat
pulmonary arterial hypertension (PAH). SteadyMed intends to
commercialize Trevyent in the U.S. and has signed an exclusive
license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe, Canada and the Middle
East. SteadyMed has offices in San Ramon, California and Rehovot,
Israel. For additional information about SteadyMed please visit
www.steadymed.com.
Contacts:
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
The Ruth Group
David Burke
(646) 536-7009
dburke@theruthgroup.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Apr 2023 to Apr 2024